156 related articles for article (PubMed ID: 23599815)
1. The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report.
Ursuleac I; Colita A; Adam T; Jardan C; Ilea A; Coriu D
J Med Life; 2013 Mar; 6(1):34-7. PubMed ID: 23599815
[TBL] [Abstract][Full Text] [Related]
2. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
Bee PC; Gan GG; Nadarajan VS; Latiff NA; Menaka N
Int J Hematol; 2010 Jan; 91(1):136-9. PubMed ID: 20047097
[TBL] [Abstract][Full Text] [Related]
3. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
Pingali SR; Mathiason MA; Lovrich SD; Go RS
Clin Lymphoma Myeloma; 2009 Oct; 9(5):E25-9. PubMed ID: 19858050
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.
Xu W; Chen B; Tong X
Int J Hematol; 2014 Jan; 99(1):87-90. PubMed ID: 24293258
[TBL] [Abstract][Full Text] [Related]
5. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
[No Abstract] [Full Text] [Related]
6. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
[No Abstract] [Full Text] [Related]
7. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
Swaminathan M; Patel KP; Huynh-Lu J; Tang G; Zuo Z; Miranda R; Verstovsek S
Acta Haematol; 2019; 141(1):23-27. PubMed ID: 30463063
[TBL] [Abstract][Full Text] [Related]
8. A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias.
Cox MC; Maffei L; Buffolino S; Del Poeta G; Venditti A; Cantonetti M; Aronica G; Aquilina P; Masi M; Amadori S
Am J Clin Pathol; 1998 Jan; 109(1):24-31. PubMed ID: 9426514
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
Zhao R; Follows GA; Beer PA; Scott LM; Huntly BJ; Green AR; Alexander DR
N Engl J Med; 2008 Dec; 359(26):2778-89. PubMed ID: 19109573
[TBL] [Abstract][Full Text] [Related]
10. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E
Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622
[TBL] [Abstract][Full Text] [Related]
11. [Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].
Takizawa M; Yokohama A; Sekigami T; Koiso H; Ishizaki T; Mitsui T; Ogawa Y; Saitoh T; Handa H; Tsukamoto N; Murakami H; Nojima Y
Rinsho Ketsueki; 2014 Jun; 55(6):687-91. PubMed ID: 24975338
[TBL] [Abstract][Full Text] [Related]
12. Co-existence of
Frikha R; Turki F; Kassar O; Elloumi M; Kamoun H
J Oncol Pharm Pract; 2021 Oct; 27(7):1784-1789. PubMed ID: 33567976
[TBL] [Abstract][Full Text] [Related]
13. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
Luque Paz D; Ianotto JC; Chauveau A; Guibourg B; Lecucq L; Lippert E; Ugo V
Ann Hematol; 2016 Jan; 95(2):349-50. PubMed ID: 26459144
[No Abstract] [Full Text] [Related]
14. Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.
Park SH; Chi HS; Cho YU; Jang S; Park CJ; Kim DY; Lee JH; Lee KH
Ann Lab Med; 2013 May; 33(3):229-32. PubMed ID: 23667855
[No Abstract] [Full Text] [Related]
15. Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.
Bader G; Dreiling B
J Investig Med High Impact Case Rep; 2019; 7():2324709619832322. PubMed ID: 30803277
[TBL] [Abstract][Full Text] [Related]
16. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
James C
Hematology Am Soc Hematol Educ Program; 2008; ():69-75. PubMed ID: 19074061
[TBL] [Abstract][Full Text] [Related]
17. JAK2-V617F and BCR-ABL--double jeopardy?
Krämer A
Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
[No Abstract] [Full Text] [Related]
18. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
19. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.
Shaikh AB; Aribandi A; Gupta A; Subramanian SK; Goyal M
Indian J Pathol Microbiol; 2021; 64(4):820-823. PubMed ID: 34673614
[TBL] [Abstract][Full Text] [Related]
20. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.
Jallades L; Hayette S; Tigaud I; Johnston A; Coiffier B; Magaud JP; Ffrench M
Leuk Res; 2008 Oct; 32(10):1608-10. PubMed ID: 18448166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]